Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XR-NTX vs Taper for Buprenorphine Discontinuation
NCT03232346Phase 3Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Aug 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of naltrexone in opioid use disorder (OUD) (2 arms), sponsored by New York State Psychiatric Institute. Primary endpoint: Percent of Patients Successfully Transitioned Off Buprenorphine at Week 25. Started Aug 2017; status: completed.
02
Drugs
naltrexone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03232346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03232346.